The approval introduces the therapy ... In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder ...
only approves the drug ketamine for use in general anesthetics. However, Medicare may cover the drug Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback